The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.

The University of Texas System (UT)

Status: Completed

Conditions: Bony Metastases From Castrate Refractory Prostate Cancer

Treatments: Drug: Radium-223 dichloride

Study type: Observational

Funder types: Other

Identifiers

NCT03368989

HSC-MS-14-0113

Details and patient eligibility

About

To describe the changes seen on bone scan and correlate them with changes in relative chemical biomarkers, patient's functional status and level of pain.

Enrollment: 21 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prostate cancer patients scheduled for treatment with Radium-223.

Exclusion criteria

• Patients not completing their treatment regimen for any reason

Trial design

21 participants in 1 patient group

treatment with radium-223 Dichloride (Xofigo)

Treatment:

Drug: Radium-223 dichloride